Revolution Medicines Inc (RVMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Revolution Medicines Inc (RVMD) has a cash flow conversion efficiency ratio of -0.236x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-354.17 Million) by net assets ($1.50 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Revolution Medicines Inc net asset quality index to measure how much of total assets are equity-financed.
Revolution Medicines Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Revolution Medicines Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Revolution Medicines Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Revolution Medicines Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Revolution Medicines Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Power Corporation Of Canada
TO:POW
|
0.042x |
|
ArcelorMittal SA
XETRA:ARRD
|
0.000x |
|
Flex Ltd
F:FXI
|
0.082x |
|
Telstra Group Ltd
AU:TLS
|
0.206x |
|
Nan Ya Plastics Corp
TW:1303
|
0.000x |
|
ArcelorMittal SA
MC:MTS
|
0.000x |
|
Deutsche Börse AG
XETRA:DB1
|
0.124x |
|
Shandong Hongchuang Aluminum Industry Holding Co Ltd
SHE:002379
|
-0.013x |
Annual Cash Flow Conversion Efficiency for Revolution Medicines Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Revolution Medicines Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Revolution Medicines Inc (RVMD) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.63 Billion | $-897.74 Million | -0.550x | -123.63% |
| 2024-12-31 | $2.27 Billion | $-557.44 Million | -0.246x | -28.19% |
| 2023-12-31 | $1.83 Billion | $-350.57 Million | -0.192x | +41.38% |
| 2022-12-31 | $685.19 Million | $-224.40 Million | -0.328x | -34.08% |
| 2021-12-31 | $602.57 Million | $-147.18 Million | -0.244x | -15.87% |
| 2020-12-31 | $474.68 Million | $-100.06 Million | -0.211x | +35.19% |
| 2019-12-31 | $152.53 Million | $-49.62 Million | -0.325x | -2691.99% |
| 2018-12-31 | $96.66 Million | $1.21 Million | 0.013x | +100.23% |
| 2017-12-31 | $4.53 Million | $-25.15 Million | -5.550x | -- |
About Revolution Medicines Inc
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS comp… Read more